1 |
Zhu Y, Wang X, Chen Z, Zhou L, Di X, Fan P, He Z. Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis. J Clin Med 2022;12. [PMID: 36614964 DOI: 10.3390/jcm12010162] [Reference Citation Analysis]
|
2 |
Li W, Chen W, Wang J, Zhao G, Chen L, Wan Y, Luo Q, Li W, Huang H, Li W, Li W, Yang Y, Chen D, Su Q. A PDX model combined with CD-DST assay to evaluate the antitumor properties of KRpep-2d and oxaliplatin in KRAS (G12D) mutant colorectal cancer. Heliyon 2022;8:e12518. [PMID: 36590511 DOI: 10.1016/j.heliyon.2022.e12518] [Reference Citation Analysis]
|
3 |
Ji Y, Li X, Qi Y, Zhao J, Zhang W, Qu P. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo. Molecules 2022;27. [PMID: 36558006 DOI: 10.3390/molecules27248873] [Reference Citation Analysis]
|
4 |
Saikia M, Bhattacharyya DK, Kalita JK. CBDCEM: An effective centrality based differential co-expression method for critical gene finding. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101688] [Reference Citation Analysis]
|